Selected article for: "gene therapy HIV clinical trial and HIV clinical trial"
Author: Metzger, Vincent T.; Lloyd-Smith, James O.; Weinberger, Leor S.
Title: Autonomous Targeting of Infectious Superspreaders Using Engineered Transmissible Therapies
  • Document date: 2011_3_17
    • ID: 0gt21051_11
    Snippet: Strikingly, TIP intervention reduces disease prevalence and incidence more effectively than either widespread ART or a 30% or 50% protective vaccine against HIV/AIDS (Figure 2a-b) . The least effective TIP analyzed-which reduces HIV in vivo viral load by 0.5-Log (from 10 5 to 10 4.5 copies/mL)-leads to a reduction in HIV/AIDS prevalence from 29% to 6.5% in 50 years, despite initial deployment to only 1% of individuals while a TIP that generates a.....
    Document: Strikingly, TIP intervention reduces disease prevalence and incidence more effectively than either widespread ART or a 30% or 50% protective vaccine against HIV/AIDS (Figure 2a-b) . The least effective TIP analyzed-which reduces HIV in vivo viral load by 0.5-Log (from 10 5 to 10 4.5 copies/mL)-leads to a reduction in HIV/AIDS prevalence from 29% to 6.5% in 50 years, despite initial deployment to only 1% of individuals while a TIP that generates a 1.5-Log decrease in HIV viral-load-as transiently achieved in a Phase-I clinical trial for an HIV gene-therapy [17] would reduce HIV/AIDS prevalence from 29% to below 1% prevalence in 30 years (Figure 2a) . In comparison, a 30%

    Search related documents:
    Co phrase search for related documents
    • clinical trial and gene therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • clinical trial and HIV AIDS prevalence: 1, 2
    • clinical trial and HIV gene therapy: 1, 2
    • clinical trial and HIV gene therapy clinical trial: 1, 2
    • clinical trial and HIV reduce: 1, 2
    • clinical trial and HIV viral load: 1, 2, 3, 4
    • clinical trial and Phase HIV gene therapy clinical trial: 1
    • clinical trial and protective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical trial and tip analyze: 1
    • clinical trial and tip intervention: 1, 2, 3, 4, 5
    • disease prevalence and HIV AIDS prevalence: 1, 2, 3, 4, 5
    • disease prevalence and HIV AIDS prevalence reduce: 1
    • disease prevalence and HIV gene therapy: 1
    • disease prevalence and HIV reduce: 1, 2
    • disease prevalence and HIV viral load: 1
    • disease prevalence and incidence disease prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease prevalence and incidence disease prevalence reduce: 1, 2
    • disease prevalence and protective vaccine: 1
    • disease prevalence and tip intervention: 1, 2, 3